FDA Approval mRNA Vaccine RSV: Market Impact & Future Outlook
The FDA's approval of the mRNA vaccine for RSV marks a significant advancement in respiratory syncytial virus prevention, with profound market implications and future potential.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 26, 2026
Key Takeaways
- Main news: The U.S. Food and Drug Administration (FDA) approved Moderna's mRESVIA (mRNA-1345) on May 31, 2024, marking the first FDA mRNA vaccine approval for respiratory syncytial virus (RSV).
- Clinical impact: The approval was based on the Phase 3 ConquerRSV trial, which demonstrated 83.7% vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD) with at least two symptoms in adults aged 60 years and older.
- Market implications: Moderna's mRESVIA is set to become a key player in the RSV prevention market for older adults, potentially reshaping the competitive landscape.
- Next steps: The focus will be on the vaccine's rollout, market adoption, and potential expansion of indications.
On May 31, 2024, the FDA granted approval to Moderna's mRESVIA (mRNA-1345), making it the first FDA mRNA vaccine approval for the prevention of RSV-associated lower respiratory tract disease (LRTD) in adults aged 60 years and older. This landmark decision is based on the robust efficacy data from the Phase 3 ConquerRSV trial, marking a significant advancement in preventive medicine for a vulnerable population. Why it matters: mRESVIA is the first FDA-approved mRNA vaccine for prevention of RSV-associated lower respiratory tract disease in older adults, addressing a significant unmet need in a vulnerable population.
Drug Overview
MRESVIA (mRNA-1345) is an mRNA therapy designed to prevent RSV-associated lower respiratory tract disease. The vaccine works by delivering mRNA that encodes for a stabilized prefusion F protein, stimulating an immune response against RSV. It is indicated for the prevention of RSV-LRTD in adults aged 60 years and older.
Clinical Insights
The approval of mRESVIA was primarily supported by data from the Phase 3 ConquerRSV trial. This trial enrolled approximately 35,541 to 37,000 participants across 22 countries. The primary endpoint was vaccine efficacy against RSV-associated lower respiratory tract disease with at least two symptoms. The trial demonstrated a vaccine efficacy of 83.7% against RSV-LRTD with ≥2 symptoms.
Regulatory Context
The FDA approved mRESVIA on May 31, 2024, based on the Phase 3 ConquerRSV trial data. No information on submission dates, PDUFA timelines, or conditional/full approval status was provided.
Market Impact
The FDA approval of mRESVIA positions Moderna as a market leader in RSV prevention for older adults, introducing mRNA vaccine technology into this therapeutic area. [Source: U.S. Food and Drug Administration] The target population includes adults aged 60 years and older at risk of RSV-associated lower respiratory tract disease. Compared with existing options, mRESVIA is the first mRNA-based RSV vaccine approved, offering a novel preventive option for older adults at risk of severe RSV disease.
Future Outlook
The approval of mRESVIA is expected to intensify competition in the vaccine landscape. What to watch next: The focus will be on the vaccine's rollout, market adoption, and potential expansion of indications. Moderna may explore potential label expansions or combination vaccines targeting multiple respiratory pathogens. The role of mRNA-1345 technology in shaping next-generation RSV vaccines and broader respiratory virus prevention strategies will also be a key area of interest.
Frequently Asked Questions
What is mRESVIA?
MRESVIA (mRNA-1345) is the first mRNA-based vaccine approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older.
What age group is mRESVIA approved for?
MRESVIA is approved for use in adults aged 60 years and older.
What were the results of the Phase 3 ConquerRSV trial?
The Phase 3 ConquerRSV trial demonstrated that mRESVIA has a vaccine efficacy of 83.7% against RSV-associated lower respiratory tract disease with at least two symptoms.
References
- Source 1: FDA Press Release, May 31, 2024.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-26.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
